Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Peptides for Immunoenzymatic Assays Immobilized on Microplates

By LabMedica International staff writers
Posted on 28 Aug 2012
Synthetic peptides are widely used in indirect enzyme-linked immunosorbent assays (ELISA) to detect and characterize specific antibodies in clinical samples. More...


A simple, fast, and inexpensive protocol has been described that shows how immobilized synthetic peptides can be bound to plastic surfaces for standard ELISA, which could be used as an alternative to the common technique of conjugating peptide antigens to carrier proteins.

Scientists at the University of Sassari (Italy) devised the technique, which is based on the use of maleimide-activated bovine serum albumin or keyhole limpet hemocyanin as a protein anchor adsorbed on the polystyrene surface of the microtiter plate. Following adsorption of the carrier protein, sulfhydryl-containing peptides are cross-linked with an in-well reaction, allowing their correct orientation and availability to antibody binding, avoiding the time consuming steps needed to purify the hapten–carrier complexes.

Conventional in-solution maleimide-mediated coupling reaction (ISC) was performed by using the Imject Maleimide Activated Immunogen Conjugation kit (Pierce; Rockford, IL, USA). Nine synthetic peptides (Nurex; Sassari, Italy) with length ranging from 10 to 15 amino acids were designed to display different hydrophobic/hydrophilic characteristics and to carry either an N or C terminal cysteine, to allow cross-linking with maleimide-activated carrier proteins. The immunoreactivity of peptides was tested by using both monoclonal and polyclonal antibodies in standard ELISA assays, and compared with established coating methods.

The efficiency of direct cross-linking method (DCLM) was tested with four different peptides and subsequent standard indirect ELISA with polyclonal antibodies was performed. All the sera specifically recognized the corresponding specific antigens when directly cross-linked onto the multiwell plate. Results in terms of signal strength were comparable to that obtained with ELISAs performed by using plates coated with ISC conjugates.

The authors concluded that DCLM proved to be simple, reproducible, cost-effective, and suitable with peptides of different lengths and hydrophobic/hydrophilic characteristics. The DCLM can be considered a straightforward, faster, and much more convenient alternative to standard coupling protocols, allowing saving time and cut costs in ELISA applications. When considering its time- and cost-effectiveness, DCLM may prove to be applicable also to automated systems for high-throughput peptide screenings. The study was published in the August 2012 edition of the Journal of Immunological Methods.

Related Links:

The University of Sassari
Pierce
Nurex



Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated MALDI-TOF MS System
EXS 3000
8-Channel Pipette
SAPPHIRE 20–300 µL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.